Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease of the colon with a variable course. Despite advances in treatment, only approximately 40% of patients achieve clinical remission at the end of a year, prompting the exploration of new treatment modalities. This review explores novel therapeutic approaches to UC, including promising drugs in various stages of development, efforts to maximize the efficacy of currently available treatment options, and non-medication-based modalities. Treatment approaches which show promise in impacting the future of UC management are highlighted.

Original languageEnglish
Pages (from-to)199-213
Number of pages15
JournalAnnual Review of Medicine
StatePublished - 27 Jan 2021


  • Crohn's disease
  • Ulcerative colitis
  • anti-adhesion therapy
  • anti-interleukin inhibitor
  • inflammatory bowel disease
  • janus kinase inhibitor
  • sphingosine receptor modulator


Dive into the research topics of 'New Therapeutics for Ulcerative Colitis'. Together they form a unique fingerprint.

Cite this